Notably, our new transgenic human T-cell lines (either GLUT1-T or GLUT1/TFAM-T) were found to suppress AML blasts’ glucose uptake and thereby result in the lessened leukemia burden in vitro (Figure 4 and Figure 5C,D). This evidence concerns the gene SLC2A1 and leukemia.